Publication | Open Access

Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+)

Translational MedicineAllergyInterim AnalysesMedicineSubcutaneous Efgartigimod Ph20Common DiseasesDermatologyNeuromuscular PathologyNeuromusculoskeletal DisorderMyasthenia Gravis